Glenmark Launches Novel FDC for Treating Asthma in India

The new fixed-dose combination (FDC) will aid in managing uncontrolled asthma by improving pulmonary (lung) function, controling symptoms, and decreasing exacerbations.

Bronchial asthma (commonly known as asthma) is a long-term and major non-communicable disease (NCD) which impacts more than 34 million individuals (children and adults) in India. The disease involves inflammation and constriction or narrowing of the small airways of the lungs, causing shortness of breath, cough, wheezing, mucous production, and chest tightness and/or pain.

Asthma may be either exercise-induced, occupational (due to chemical fumes and gases), or allergy-induced (due to allergens such as pollen, molds, dust, and pet dander). Other types of asthma include nocturnal asthma (which gets worse at night), aspirin-induced asthma, and eosinophilic asthma. Strong emotions such as extreme sadness, anxiety, stress, and laughter could also induce asthma. The condition is diagnosed based on history, clinical signs and symptoms, and investigations such as spirometry, methacholine challenge, exhaled nitric oxide test, and imaging modalities such as computed tomography (CT).

Out of the total asthmatic patients undergoing conventional treatment in India, up to 49 percent have uncontrolled asthma. Each year, 4.6 lakh individuals die from asthma across the globe, and India contributes to 1.98 lakh deaths.

Glenmark Pharmaceuticals has recently launched a novel FDC medication in India for uncontrolled asthmatics. According to the Global Burden of Disease report of the Institute for Health Metrics and Evaluation (IHME), asthma has accounted for approximately 28 percent of disability-adjusted life years (DALYs) among Indians, causing three-fold higher deaths and two-fold higher DALYs in comparison to the global asthma proportion.

The Mumbai-based pharma major has launched the FDC combination- Indacaterol + Mometasone under the brand name Indamet which would be available in three dose strengths wherein the dose of Indacaterol would be fixed at 150 mcg whereas the dose of Mometasone would vary as 80 mcg, 160 mcg, and 320 mcg. Indamet would have to be taken once daily and can be consumed by adults and children aged above 12 years, according to the company.

The respiratory/pulmonary system has been a key area of focus for Glenmark Pharmaceuticals, and the company has been a lead one in providing the latest therapeutic options for patients. In India, Glenmark Pharmaceuticals is the first company to market the FDC of Indacaterol, a long-acting beta(β)-agonist, and mometasone furoate, an inhaled corticosteroid, authorized by the Drug Controller General of India (DCGI).

Alok Malik, Glenmark Pharmaceuticals Group Vice President & Head of India Formulations said, “We are proud to introduce this novel fixed-dose combination Indamet, which is the first of its kind in India, offering an affordable treatment option to both adults and adolescents 12 years of age and older suffering from uncontrolled asthma.”


Pooja Toshniwal Paharia

Dr. Pooja Toshniwal Paharia is a Consultant Oral and Maxillofacial Physician and Radiologist, M.DS (Oral Medicine and Radiology) from Mumbai. She strongly believes in evidence-based radiodiagnosis and therapeutic regimens for benign, potentially malignant, or malignant lesions and conditions either arising from the oral and maxillofacial structures or manifesting in the associated regions.

Show More

Related Articles

Leave a Reply

Back to top button